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Abstract 
Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity 
accounting for less than 1% of all melanomas. Histologically, it is located in the dermis or 
subcutaneous tissue, and it shows no connections with the overlying epidermis. The 
differential diagnosis is principally made along with that of metastatic cutaneous melanoma. 
Case Report: A 72-year-old Caucasian woman with a history of multiple cancers (metachro-
nous bilateral breast cancer, meningioma, clear cell renal cell carcinoma, uterine fibromatosis 
and intestinal adenomatous polyposis), came to our attention with a nodular lesion on her 
back. After removal of the lesion, the histology report indicated malignant PDM or metastatic 
malignant melanoma. The clinical and instrumental evaluation of the patient did not reveal 
any other primary tumour, suggesting the primitive nature of the lesion. The absence of an 
epithelial component argued for a histological diagnosis of PDM. Subsequently, the patient 
underwent a wide surgical excision with sentinel node biopsy, which was positive for 
metastatic melanoma. Finally, the mutational status was studied in the main genes that 
regulate proliferation, apoptosis and cellular senescence. No pathogenetic mutations in 
CDKN2A, BRAF, NRAS, KRAS, cKIT, TP53 and PTEN genes were observed. This suggests that 
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differential diagnosis between PDM and isolated metastatic melanoma depends on the 
negativity of imaging studies and clinical findings for other primary lesions. This distinction is 
important because 5-year survival rates in such cases are higher than in metastatic cases (80–
100 vs. 5–20%, respectively). © 2013 S. Karger AG, Basel 
Introduction 
Primary dermal melanoma (PDM) has been proposed as a specific subtype of melanoma 
[1, 2]. Such a skin lesion is confined to the dermis and/or subcutaneous fat, showing no 
connections with the overlying epidermis and simulating a melanoma metastasis [1]. PDM 
should be differentiated from primary nodular melanoma, cutaneous metastatic melanoma 
and clear cell sarcoma, due to its excellent prognosis as compared to that of patients with 
these three latter diseases [2–4]. Generally, a diagnosis of PDM should be considered in all 
patients with a solitary melanoma confined to the dermis and subcutaneous tissue when 
there is no evidence of a primary tumour or disease at other sites following appropriate 
staging studies. This uncommon clinical entity is reported in the literature with an incidence 
ranging between 0.4 and 0.9% [3]. 
Among the main pathways which have been found to be involved in melanomagenesis, 
including those inducing cell proliferation (proliferative pathways), overcoming cell 
senescence (senescence pathway) or affecting apoptosis (apoptotic pathways), molecular 
characterization of PDM lesions revealed lower expression levels of p53 and cyclin D1 
proteins [3] as well as an up-regulation of the cKIT gene [4]. 
We report a case of PDM in a 72-year-old Caucasian woman who had a peculiar history 
of multiple previous malignancies. A molecular characterization of the lesion was performed. 
Case Report 
A 72-year-old Caucasian woman came to our attention for a right paravertebral pur-
plish-red nodular lesion on the back, with a few focal pigmentations and a small semilunar 
perinodular area of brownish pigmentation (fig. 1a). The patient could not report the onset 
of the lesion. The differential diagnosis included, in this case, basal cell carcinoma, malignant 
melanoma, vascular lesions, epidermoid carcinoma and dermatofibroma. 
The patient’s clinical history was characterized by multiple tumours, including bilateral 
metachronous breast cancer for which she had undergone bilateral mastectomy and axillary 
lymphadenectomy, clear cell renal cell carcinoma, uterine fibromatosis and intestinal 
polyposis with low- and high-grade dysplasia. Despite the macroscopic aspect which 
suggested pigmented basal cell carcinoma, the possibility of the lesion being melanocytic 
made us opt for an excisional biopsy with a 2-mm margin. 
The skin lesion specimen showed a poorly differentiated neoplastic dermal infiltration 
with morphological aspects of melanocytic proliferation (fig. 1b). The tumour cells displayed 
round or oval shapes with brisk mitotic activity, and they were arranged in a nodular 
architecture with rounded margins. Lymphocytic and plasmacellular infiltration of the lesion 
was observed, without formation of lymphoid nodules. An intraepidermal component, 
ulceration and regression aspects were not evident, even with an examination of multiple 
sections; a preexisting nevus, spindle neoplastic cells or bands of mature intercellular 
collagen were also not found. A distinct grenz zone was appreciable between the dermal 
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immunohistochemistry (S100 protein and HMB-45 positive). The proliferative index 
evaluated with Mib-1 was 25%. 
The histopathological report was summarized as ‘malignant melanoma (thickness 
2 mm); the absence of intraepidermal atypical melanocytes is compatible with metastatic 
malignant melanoma or PDM’. Desmoplastic melanoma was excluded on the basis of 
cytology and because of the lack of a desmoplastic reaction, while nodular melanoma was 
excluded due to the absence of an intraepidermal component. With the aim of identifying a 
possible primary lesion, the following tests were performed: dermatological examination; 
total body CT; ophthalmologic examination; pancolonoscopy; ear, nose and throat examina-
tion; esophagogastroduodenoscopy, and gynaecological examination. No evidence of another 
primary melanoma was found; however, a parallel finding of frontal meningioma was noted. 
The absence of another primary lesion led us to make the diagnosis of PDM per exclusionem. 
The second surgical step included the excision of the biopsy scar with 2-cm margins and 
sentinel lymph node biopsy. The preoperative lymphoscintigraphy showed 3 areas of 
uptake – 2 of them involving the soft tissue at the level of the posterior pillar of both the 
axillae, and the remaining 1 in the left paravertebral area, adjacent to the previous surgical 
site. However, only a single sentinel node presenting micrometastasis of melanoma was 
found in the latter area. 
A bilateral axillary ultrasound examination was performed to investigate the areas of 
lymphoscintigraphic uptake; subsequently, the patient underwent an additional surgical 
procedure for the removal of a lymph node with ambiguous ultrasonographic features found 
within the residual left axillary fatty tissue (the patient had had ipsilateral axillary lymphad-
enectomy several years before for breast cancer). The histological examination of the 
specimen revealed adipose tissue and a lymph node with reactive patterns. The patient is 
currently alive and free of disease 14 months since her diagnosis. 
Mutational Analysis 
Different pathways for the development of melanoma have been demonstrated [5]. 
Melanomas on skin not chronically exposed to the sun – such as the anatomical location of 
the skin lesion in our case – have been reported to usually carry either a mutated NRAS gene 
or mutated BRAF gene or concurrently mutated BRAF and PTEN genes [6]. Furthermore, the 
coexistence of additional tumours in our patient was a strong indication to either investigate 
the CDKN2A and TP53 genes, which have been demonstrated to be involved in multiple 
cancer pathogenesis and predisposition [7], or assess the occurrence of the E318K sequence 
variation in the MITF (microphthalmia-associated transcription factor) oncogene, which has 
been reported in patients with an association between melanoma and renal cancer [8]. 
Finally, the mutation analysis was carried out in the cKIT gene, which has been demonstrat-
ed to be involved in PDM pathogenesis [4]. Genomic DNA was isolated from a peripheral 
blood sample and tumour tissue, using standard methods. The full coding sequences and 
splice junctions of p16CDKN2A (exons 1α, 2 and 3), p14CDKN2A (exon 1β) and PTEN (exons 1–9) 
genes as well as the most frequently affected exons of NRAS/KRAS (2–3), BRAF (15), cKIT (9, 
11, 13, 17 and 18) and TP53 (5–8) genes were screened for mutations on somatic DNA 
isolated from paraffin-embedded tumour tissue samples by directly sequencing the 
amplified PCR products through an automated fluorescence-cycle sequencer (ABI PRISM 
3130, Applied Biosystems, Foster City, Calif., USA). For p16CDKN2A, p14CDKN2A and MITF genes, 
mutation analysis was also carried out on germline DNA obtained from peripheral blood of 
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No mutation was identified in such crucial genes involved in melanoma susceptibility 
and pathogenesis. In particular, alteration of the CDKN2A gene, encoding p16CDKN2A, which is 
the main component of the CyclinD1-RB pathway, and p14CDKN2A, which has been functional-
ly linked to the MDM2-p53 pathway, have been widely reported as the most common causes 
of inherited susceptibility to melanoma at the germline level, participating also in melanoma 
progression at the somatic level [10, 11]. Lack of TP53 mutations in melanoma cells from our 
patient’s tissues is consistent with the absence of involvement of both the p16CDKN2A-
CyclinD1-RB and p14CDKN2A-MDM2-TP53 cascades in the pathogenesis of such lesions. 
Analogously, activation of both the MAPK-ERK pathway (including the cascade of 
NRAS/KRAS, BRAF, MEK1/2, and ERK1/2 proteins), a major signaling cascade deputed to 
the control of cell growth and proliferation, and the PTEN-dependent pathway (including the 
PI3K and AKT effectors), committed to regulate cell survival and apoptosis, were not 
involved in inducing the malignant transformation in our case. As a further confirmation that 
genetic alterations in such major pathways played no role in pathogenesis in our PDM case, a 
wild-type cKIT variant (this gene has been demonstrated to indeed recruit and activate a 
number of intracellular signalling pathways implicated in melanocytic transformation and 
progression, including the PI3K-AKT and MAPK pathways [12]) as well as the absence of the 
MITF E318K variant were observed here. Therefore, one could speculate that the cascade of 
alterations underlying melanomagenesis may be due to additional low-frequency genetic 
and molecular events in our patient. 
Discussion 
Dermal or subcutaneous metastasis of melanoma of unknown primary origin, according 
to the 2002 AJCC (American Joint Committee on Cancer) staging guidelines, is classified as 
stage IV M1a disease and has a poor prognosis (5-year survival rate 18.8%). Nevertheless, 
small series of dermal or subcutaneous solitary lesions have been reported with consistently 
better recurrence and survival rates, depending on the thickness and presence of ulceration. 
In 2004, Swetter et al. [1] reported a series of 5 patients with such lesions and speculated 
that those were cases of a distinct subtype of melanoma and should be referred to by the 
term primary dermal melanoma. It is, therefore, of utmost importance to differentiate PDM 
from a solitary dermal or subcutaneous metastasis of melanoma. 
Regarding the pathogenesis of PDM, several hypotheses have been proposed. Some 
authors speculate that the tumour may arise from nonepidermal melanocytes or intradermal 
nevi, while others believe that it is an epidermally regressed primary [13, 14]. Despite the 
existence of some evidence in favour of one or the other theory, none has been demonstrat-
ed definitely. Given the rarity of PDM and the small number of cases reported, demographic 
information and data on the anatomic sites most commonly involved are inconsistent. 
Furthermore, the impact of these factors on prognosis is not known. Lee et al. [15], in a 
series of 101 solitary dermal melanomas, did not find any site-related differences which 
might explain the generally better prognosis of these tumours. 
From the clinical point of view, a thorough dermatological examination of the skin and 
of the visible mucosae as well as gynaecological and ophthalmological examinations, a 
pancolonoscopy and a total body CT should be performed to look for and possibly exclude 
hidden primaries. The role of sentinel lymph node biopsy in clinical management is not yet 
clear, but it seems to be useful for the detection of micrometastasis, as occurred in our case. 
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also undertake a genetic analysis. The patient also had a history of multiple previous 
malignancies that could have been a clue for a genetic predisposition. 
The genetic analysis performed at both the germline and somatic levels in our patient 
revealed that the main genes responsible for the susceptibility and pathogenesis of 
melanoma, respectively, were not affected. This suggests that alternative, low-frequency 
altered genes/pathways may be involved. A more comprehensive genetic profiling based on 
microarray technology will be helpful in making correlations between molecular signatures 
and clinical features; to date, gene expression arrays have been employed in such a 
melanoma classification [16]. Nevertheless, the advancements of biotechnology, mostly 
represented by next-generation sequencing approaches [17], will provide even more reliable 
tools for detailed gene-based analyses, allowing physicians to better characterize molecular 
biomarkers in order to achieve a more accurate diagnosis as well as predict prognosis and 
response to treatment in patients with melanoma. 
Conclusions 
The differential diagnosis between PDM and isolated metastatic melanoma is generally 
performed per exclusionem and is based on the negativity of clinical findings and imaging 
studies for primary lesions. This distinction is important because 5-year survival rates in 
PDM are consistently higher than in metastatic cases (80–100 vs. 5–20%, respectively). 
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